Sarcoidosis
Conditions
Keywords
neurosarcoidosis, pulmonary hyeprtension, infliximab, repository corticotropin
Brief summary
Registry with evaluation and genetic information of patients with advanced sarcoidosis and matched sarcoidosis
Interventions
OTHERobservation
observe patients every 6 months
Sponsors
University of Cincinnati
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
15 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Patients with diagnosis of sarcoidosis based on ATS/WASOG criteria 22 * Age ≥ 18 years. * Life expectancy of at least 2 years. * Pulmonary function tests (spirometry) within one month of entry or willing to under pulmonary function testing on the day of study enrollment * Sarcoidosis as characterized as either advanced or non-advanced (see protocol for definition of advanced disease) * Subjects must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.
Exclusion criteria
* Subjects with a medical disorder, condition, or history of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator * Inability to comply with the protocol and/or not willing or not available for follow-up assessments. * Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Death | 2 years | Determine how many people die during follow up |
Countries
United States
Contacts
Primary ContactRobert Baughman
Outcome results
None listed